| Table of Contents |  |
|
Original Article
| ||||||
| Chemotherapy induced anemia in patients with malignant diseases: A Montenegro study | ||||||
| Vladimir Todorovic1, Jadranka Lakicevic2, Nada Cicmil Saric2, Anka Popovic3, Vesko Vujicic3, Danko Zivkovic4, Aleksandra Kovacevic5, Rozalinda Isjanovska6 | ||||||
|
1Oncology and Radiotherapy Clinic, Clinical Centre of Montenegro, Centre for Haematology, Clinical Centre of Montenegro.
2Oncology and Radiotherapy Clinic, Clinical Centre of Montenegro. 3Centre for Haematology, Clinical Centre of Montenegro. 4Special Hospital for Lung Diseases - Brezovik. 5Faculty of Medicine, University of Montenegro. 6Faculty of Medicine Skopje. | ||||||
| ||||||
|
[HTML Full Text]
[PDF Full Text]
[Print This Article]
[Similar article in Pumed] [Similar article in Google Scholar] |
| How to cite this article |
| Todorovic V, Lakicevic J, Saric NC, Popovic A, Vujicic V, Zivkovic D, Kovacevic A, Isjanovska R. Chemotherapy induced anemia in patients with malignant diseases: A Montenegro study. Edorium J Cancer 2015;2:1–7. |
|
Abstract
|
|
Aims:
Oncology patients treated by chemotherapy (CT) often develop different levels of anemia. We analyzed efficacy and safety of three times weekly administration of epoetin beta in hematologic and solid tumors in Montenegro.
Methods: One hundred and twenty anemic patients with solid tumors (75 patients) and non-myeloid hematological malignancies (45 patients) were treated with epoetin beta in the period from January 2009 till May 2012. We analyzed efficacy in terms of hemoglobin (Hb) level, transfusion requirement, dosing schedule and safety in this open label, single arm, non-interventional study. Anemic patients with Hb level <11 g/dL, treated with chemotherapy were included in this first multicentre oncology study in Montenegro. Statistical multivariate analysis method was used. Results: In our study, most of patients had moderate anaemia, while 5.8% had severe level. Statistical significance was found in level of Hb during epoetin beta therapy compare to baseline and other study visits (p = 0.01). The percentage of patients with normal Hb values was increasing during the treatment. The need for blood transfusion was decreasing during epoetin beta therapy (first visit 8.3%, fifth visit 1.7%). Majority of patients (68%) did not report any adverse event. Two patients had thromboembolic events. Conclusion: Administration of epoetin beta 30.000 IU three times weekly significantly increased Hb levels in anemic patients with different solid tumors and non-myeloid hematological malignancies who were receiving chemotherapy. The number of required transfusion is decreasing during the study treatment. Therapy with epoetin beta was well tolerated. Benefits of using epoetin beta were confirmed in patients with chemotherapy induced anemia. | |
|
Keywords:
Anemia, cancer, chemotherapy, epoetin beta, safety
| |
|
[HTML Full Text]
[PDF Full Text]
|
|
Author Contributions:
Vladimir Todorovic – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published Jadranka Lakicevic – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published Nada Cicmil Saric – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published Anka Popovic – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published Vesko Vujicic – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published Danko Zivkovic – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published Aleksandra Kovacevic – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published Rozalinda Isjanovska – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published |
|
Guarantor of submission
The corresponding author is the guarantor of submission. |
|
Source of support
None |
|
Conflict of interest
Authors declare no conflict of interest. |
|
Copyright
© 2014 Vladimir Todorovic et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information. |
|
|
|
About The Authors
| |||
| |||
| |||
| |||
| |||
| |||
| |||
| |||
| |||
